# Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma

> **NCT03868943** · PHASE2 · TERMINATED · sponsor: **Wake Forest University Health Sciences** · enrollment: 2 (actual)

## Conditions studied

- Glioma
- Glioblastoma

## Interventions

- **DRUG:** Soliramfetol

## Key facts

- **NCT ID:** NCT03868943
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-27
- **Primary completion:** 2021-11-22
- **Final completion:** 2021-11-22
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Axsome has conducted a review of the ongoing IST program and are unable to continue supporting this study
- **Last updated:** 2025-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03868943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03868943, "Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03868943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*